RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @stephanielangel: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related p…
RT @Elyrya_Ylnae: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T-cell cancer targeting via the monomorphic MHC class I-related prot…
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T-cell cancer targeting via the monomorphic MHC class I-related protein MR1 https://t.co/efRVssRPS7
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
Importante hallazgo https://t.co/ScktGCLg2N
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
T cells that target only cancer cells! Interesting breakthrough!! https://t.co/eudtvHgm4B
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
Se acerca la cura del cáncer... de todo tipo de cáncer.
RT @NatImmunol: Sewell and colleagues show nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted…
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 | Nature Immunology https://t.co/BGCVsjiIJl
🔬 Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. 📝 Nat Immunol. 👨🏻🔬 Crowther MD, et al. 🌎 https://t.co/bQjfuty3oL #science #research https://t.co/q3PJI1qSOj
Major breakthrough in cancer research ? "These findings offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies." https://t.co/8xMAfgfbAk
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
Is this “research” paper legit? @PanCAN @letswinpc @pashtoonkasi @drjasonstarr https://t.co/tTx8mgrF4t
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
pdf en "détail" Nature Immunology | VOL 21 | February 2020 | 178–185 : https://t.co/7HXAsVI6BJ
Tiens donc ... ça me rappel une certaine chronique de @Sardoche_Lol sur CRISPR-Cas9 l'année dernière dans #Popcorn ! https://t.co/r8aUBbAkeb Popcorn les premiers sur l'actu !
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @Menon_Ashwin: Very interesting paper suggesting MR1 as a pan-cancer target, while remaining inert to noncancerous cells. Removing one o…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
Hey #lifescience #cancer community: thoughts? Could this new type of T-cell be the cure for cancer? February Nature https://t.co/OdUIg3wYMu
New T-cells offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies https://t.co/HpuHhT3RmK
New T-cells offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies. https://t.co/w1ivuvdwDT
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
RT @MarineCaillaud7: Really proud of this new paper being published in Nature Immunology! Check it out! https://t.co/XIM3muaEyI @TcellResea…
3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big breakthrough! Especially the fact, that the T-Cells only target cancer cells and ignore healthy cells is absolutely mind blowing!
Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. https://t.co/LRanh8NgcF
An exciting paper.
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
the paper https://t.co/covGHGlgpO
Genome-wide CRISPR–Cas9 screening reveals ubiquitous Tcell cancer targeting via the monomorphic MHC class I-related protein MR1 https://t.co/sdWeZNQq9z
@ContinuumLS @BBCBreaking @Reuters @cnnbrk Is this the relevant release https://t.co/wUlaDw7a0o What about rarer cancers with no survivors?...DIPG is desperate for new approaches, obviously neurotoxicity is huge concern CAR-T studies are just beginning..GD
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
#Top3 Mediante CRISP-Cas9 🧬 se ha diseñado un TCR que reconoce MR1 🎯(MHC-related protein). Es activo frente a varias lineas celulares tumorales de diferentes tipos tisulares in vitro e in vivo sin afectar células sanas ➡️ https://t.co/zdymG84N9d
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @BeyondLove2010: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related pr…
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 | Nature Immunology #cancer #cancercure #CRISPR #genome #HLA @SciFriday @sharonkgilbert https://t.co/BfQMQfZKEj
RT @ReskiLab: @UniFreiburg A very short story about good and "not so good" science coverage in journalism. #scicomm #Wisskomm 1) Here is th…
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @Andres_Lopez_C: 🧬 Se descubre un nuevo tipo de ‘killer T-cell’ equipado con un nuevo tipo de receptor capaz de reconocer y matar la may…
🔬 Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. 📝 Nat Immunol. 👨🏻🔬 Crowther MD, et al. 🌎 https://t.co/bQjfuty3oL #science #research https://t.co/g3V20QxHPU
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @andreahgk: https://t.co/fA3sq95isT les dejo el artículo de nature ❤️
Ok, 🤦 so hopefully sometime next week, if it wasn't tonight!
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @tonyrodz_: Las células inmunes del nuevo tratamiento han destruido con éxito, células cancerosas en pulmones, piel, sangre, colon, hues…
RT @Raissadati: New T cell found with a receptor for MR1 on cancer cells. Most excitingly, MR1 is monomorphic and thus similar in structure…
Las células inmunes del nuevo tratamiento han destruido con éxito, células cancerosas en pulmones, piel, sangre, colon, huesos, próstata, ovarios, riñones, cuello uterino y de mama. https://t.co/eHsjpxUpXB
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 | Nature Immunology #cancer #crispr https://t.co/iTJWxhHSEV
A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.co/gfZT0Ym1Kj #NBThighlight
Ugh, cool, but what is the metabolite?!? I don’t know whether I am more excited or annoyed about this study 😂
Cool pan cancer attack, but cancer might easily evade by reduced production of MR1 ligand
RT @Andres_Lopez_C: 🧬 Se descubre un nuevo tipo de ‘killer T-cell’ equipado con un nuevo tipo de receptor capaz de reconocer y matar la may…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @Andres_Lopez_C: 🧬 Se descubre un nuevo tipo de ‘killer T-cell’ equipado con un nuevo tipo de receptor capaz de reconocer y matar la may…
https://t.co/l8rHMBKjMp 癌細胞だけ狙い撃ちできるってこと??続報求む・・・
RT @Andres_Lopez_C: 🧬 Se descubre un nuevo tipo de ‘killer T-cell’ equipado con un nuevo tipo de receptor capaz de reconocer y matar la may…
RT @NatImmunol: Sewell and colleagues show nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted…
Cardiff csientiests discovered immune cell that seems to be effective killing most types of cancers. a modified T-cell with a new type of receptor (TCR) that recognizes a molecule called MR1. Immunlogy is the way to win over cancer. https://t.co/rnwlvTQ6y
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 | Nature Immunology https://t.co/tJqudjCHhX
https://t.co/jE79XSIxoq 複数の癌細胞を認識できるT細胞が腸管のMAITから単離され、これはMHC非拘束性のTCRであることが分かった。クリスパーを使ったゲノムワイドスクリーニングにより、このTCRが癌に発現するMR1を特異的に認識していることが分かった。
🔬 Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. 📝 Nat Immunol. 👨🏻🔬 Crowther MD, et al. 🌎 https://t.co/bQjfuty3oL #science #research https://t.co/0OqciyV3Yb
RT @bmz9453: Femonenalno, zlasti za zdravnike. Članek v “Nature Imunology” (2019) najdete tukaj: https://t.co/o3BRXZ1Yqe https://t.co/YXMcb…
Femonenalno, zlasti za zdravnike. Članek v “Nature Imunology” (2019) najdete tukaj: https://t.co/o3BRXZ1Yqe
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
Love seeing the progress our customers continue to make developing immunotherapies! #immunotherapy #genomics #PrecisionMedicine
RT @JSithens: Link to full original article in Nature Immunology regarding potential cure for many, if not all, cancers. https://t.co/XyPi…
RT @JochenReiser: An engineered an omnipotent weapon against cancer - wow ! @AndrewZloza @RushUniversity @RushCancer
Wow, is there a cure for cancer... https://t.co/i5fXa09OOt